市场调查报告书
商品编码
1316287
全球左心室辅助装置 (LVAD) 市场 - 2023-2030 年Global Left Ventricular Assist Device (LVAD) Market - 2023-2030 |
※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。
2022 年,全球左心室辅助装置 (LVAD) 市场规模达到 14 亿美元,预计到 2030 年将实现利润丰厚的增长,达到 23 亿美元。在预测期内(2023-2030 年),全球左心室辅助装置 (LVAD) 市场的复合年增长率预计将达到 7.2%。
左心室辅助装置(VAD)是一种机械循环支持策略,通过将血液从心脏腔室泵送至全身,在心衰患者中广泛应用。预计在预测期内,心力衰竭人数的增加、新产品的推出、技术的进步和市场的不断发展等因素将推动全球左心室辅助装置(LVAD)市场的增长。
预计在预测期内,心力衰竭病例的增加将推动全球左心室辅助装置市场的增长。心力衰竭极为典型。尽管在治疗多种心脏疾病方面取得了进展,但心力衰竭仍是全球日益关注的问题。例如,根据美国心力衰竭协会(Heart Failure Society of America)的评估,目前有近 650 万 20 岁以上的美国人患有心力衰竭。一项重要的调查评估显示,每年有超过 96 万名新的心力衰竭患者。心力衰竭不仅是一个影响相当多的人的重大问题,而且心力衰竭甚至是一个突出的杀手。在美国,心力衰竭直接导致的死亡人数约占所有心脏病死亡人数的 8.5%。据估计,心力衰竭导致的死亡人数约占心血管疾病死亡总人数的 36%。
越来越多的研究活动预计将推动全球左心室辅助装置市场的发展。例如,在确保获得 FDA 授权的首要行动中,总部位于以色列的设备制造商 Magenta Medical 正在对其用于高风险经皮冠状动脉介入治疗(HR-PCI)的 Elevate 经皮左心室辅助装置(pLVAD)启动一项不成熟的可行性调查。
据估计,在预测期内,植入左心室辅助装置的高昂费用将阻碍全球左心室辅助装置市场的发展。例如,根据美国国立卫生研究院(NIH)的数据,植入 LVAD 的平均费用为 175,420 美元。然而,LVAD 证明心力衰竭患者的生活质量得到了改善,但由于频繁的再入院和昂贵的后续护理,终生成本大幅增加。
COVID-19 在全球许多国家的流行和封锁影响了各行各业公司的财务健康。因此,在 COVID-19 公共卫生紧急事件期间,美国食品和药物管理局 (FDA) 发布了指导方针,其中包括帮助申办者和研究人员的一般注意事项,以确保试验参与者的安全、遵守良好临床实践 (GCP),并最大限度地降低试验完整性的风险。
俄罗斯与乌克兰的冲突被认为对全球左心室辅助装置(LVAD)市场的影响不大,因为该地区的心力衰竭发病率较低,而且缺乏主要的市场参与者。尽管乌克兰军队继续抵御俄罗斯军队的入侵,但由于死亡人数不断增加,医疗援助有限,乌克兰的诊所也不得不这样做。所有类型的药品都出现短缺。同样,原材料进出口的重要性预计将在预测期内对全球左心室辅助装置(LVAD)市场的增长产生轻微影响。
The global left ventricular assist device (LVAD) market reached US$ 1.4 billion in 2022 and is expected to witness lucrative growth by reaching up to US$ 2.3 billion by 2030. The global left ventricular assist device (LVAD) market is expected to exhibit a CAGR of 7.2% during the forecast period (2023-2030).
Left Ventricular Assist Devices (VAD) are mechanical circulatory support strategies planted in heart failure individuals with intense manifestation and operation by pumping blood from the chambers of the heart to the entire body. The increase in the number of heart failures, rising type launches, advancements, and increasing market developments are among the factors expected to boost the global left ventricular assist device (LVAD) market growth in the forecast period.
The increasing cases of heart failure are expected to boost the global left ventricle assist device market growth in the forecast period. Heart failure is extremely typical. Although improvement is created in the treatment of multiple states of heart conditions, heart failure is a growing concern globally. For instnace, according to the Heart Failure Society of America, the current assessments are that nearly 6.5 million Americans over the age of 20 suffer heart failure. One significant investigation assessment indicates that there are over 960,000 fresh heart failure patients yearly. Not only is heart failure a significant issue impacting a considerable number of individuals, but heart failure is even a prominent killer. Heart failure directly accounts for approximately 8.5% of all heart condition deaths in the United States. And, to some assessments, heart failure contributes to about 36% of all cardiovascular disease deaths.
Increasing research initiatives are estimated to boost the global For instance, in the foremost action in ensuring FDA authorization, Israel-based device maker Magenta Medical is initiating a premature feasibility investigation with its Elevate percutaneous Left Ventricular Assist Device (pLVAD) for high-risk percutaneous coronary intervention (HR-PCI).
The high cost of LVAD implantation is estimated to hamper the global left ventricular assist device market growth in the forecast period. For instance, according to the NIH, the mean cost of LVAD implantation was USD 175,420. However, LVADs proven heart failure patients improved quality of life but substantially increased lifetime costs because of frequent readmissions and costly follow-up care.
The financial health of companies across all industries has been impacted by the COVID-19 pandemic and lockdown in numerous nations throughout the world. Therefore, for the period of the COVID-19 public health emergency, the U.S. Food and Drug Administration (FDA) issued guidelines that include general considerations to aid sponsors and researchers, ensuring the safety of trial participants, adhering to good clinical practice (GCP), and minimizing risks to trial integrity.
The Russia-Ukraine conflict is thought to hold a moderate influence on the global left ventricular assist device (LVAD) market, as there is a low incidence of heart failure and a lack of primary market players in this region. Though continuing to countenance invasions from Russian armies, Ukrainian clinics are forced by growing numbers of deaths and limited medical aid. There are shortages across all types of medications. Again, the significance of the import and export of raw materials are expected to slightly impact the global Left Ventricular Assist Device (LVAD) market growth in the forecast period.
The global left ventricular assist device (LVAD) market is segmented based on type, pump type, application, end-user, and region.
Owing to the increase in the procedures of implantable LVAD, implantable LVAD is estimated to hold around 23.9% of the global market share by 2030. For instnace, in July 2022, a team from Emory's Heart and Vascular Center conducted its 500th continuous flow, durable left ventricular assist device (LVAD) implantation, additionally establishing Emory Healthcare's position as a national leader in the life-saving procedure.
Owing to the key player's efforts in the Europe region, the region is estimated to hold around 27.1% of the global market share. For instance, UK-based Calon Cardio-Technology Ltd. seeks to obtain the CE Mark for its MiniVAD in earlier 2024, by which period a US FDA Early Feasibility Study is expected to have been concluded. The corporation pursues to boost investments of almost USD 47 million (£34 million) to USD 60 million (£43 million) to finance its clinical investigations of the MiniVAD in the US and Europe from 2020 to 2023.
The major global players in the Left Ventricular Assist Device (LVAD) market include: CorWave, Apaxis Inc., Sunshine Heart, HeartWare International (Medtronic), Sun Medical Technology Research, Abiomed, Terumo Corporation, Evaheart, Jarvik Heart, and Thoratec (Abbott), among others.
The global left ventricular assist device (LVAD) market report would provide approximately 53 tables, 54 figures, and 195 Pages.
Australia
LIST NOT EXHAUSTIVE